Dr. Reddy’s board to review FY 2025-26 dividend

Dr. Reddy’s Laboratories Limited submitted a Form 6-K stating that its Board of Directors will consider, among other items, a proposal for recommending a final dividend for FY 2025-26, if any.

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited submitted a Form 6-K stating that its Board of Directors will consider, among other items, a proposal for recommending a final dividend for FY 2025-26, if any. The company notes this update is in continuation of an earlier intimation dated March 23, 2026.

Key Terms

final dividend, Board of Directors, foreign private issuer

3 terms

final dividend financial

"the Board of Directors will consider, inter alia, the proposal for recommending the final dividend for FY 2025-26, if any"

Board of Directors financial

"the Board of Directors will consider, inter alia, the proposal for recommending the final dividend"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dr. Reddy’s Laboratories (RDY) disclose in this Form 6-K?

Dr. Reddy’s Laboratories disclosed that its Board of Directors will consider, among other items, a proposal for recommending a final dividend for FY 2025-26, if any. The update is provided as a continuation of an earlier intimation dated March 23, 2026.

Is Dr. Reddy’s Laboratories (RDY) planning a final dividend for FY 2025-26?

The company stated that its Board of Directors will consider a proposal for recommending a final dividend for FY 2025-26, if any. This means a dividend is under consideration, but no decision or specific dividend details were disclosed in this communication.

What period would the potential final dividend at Dr. Reddy’s (RDY) relate to?

Any potential final dividend discussed in this communication would relate to the company’s financial year 2025-26. The filing only indicates that the Board will consider, inter alia, a proposal to recommend such a dividend, without providing further financial details or timing.

How does this Form 6-K relate to Dr. Reddy’s earlier March 23, 2026 intimation?

The company states this notice is in continuation of an earlier intimation dated March 23, 2026. It updates stakeholders that the Board of Directors will now consider, among other matters, a proposal for recommending a final dividend for FY 2025-26, if any.

Which exchanges are addressed in Dr. Reddy’s April 16, 2026 dividend notice?

The notice is addressed to the National Stock Exchange of India Ltd., BSE Limited, the New York Stock Exchange Inc., and NSE IFSC Ltd. It informs these exchanges that the Board will consider a proposal for recommending a final dividend for FY 2025-26, if any.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 09:38 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

April, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                                 Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                                 No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation regarding Board Meeting

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: April 16, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibits 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email: mail@drreddys.com Web:   www.drreddys.com

April 16, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation of Board Meeting for consideration of Final Dividend under Regulation 29 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015

Ref : Prior intimation dated March 23, 2026

With reference to the subject cited above and in continuation, to our earlier intimation dated March 23, 2026, this is to bring to your kind notice that the Board of Directors will consider, inter alia, the proposal for recommending the final dividend for FY 2025-26, if any.

This is for your information and records.

Thanking you,

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

​​​​​​​

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 22.4 KB